Compare EOLS & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EOLS | AVXL |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 289.1M |
| IPO Year | 2018 | 2013 |
| Metric | EOLS | AVXL |
|---|---|---|
| Price | $6.49 | $2.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $15.50 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 948.3K | 815.1K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $297,176,000.00 | N/A |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $17.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $3.86 | $2.61 |
| 52 Week High | $10.62 | $13.99 |
| Indicator | EOLS | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 69.96 | 31.25 |
| Support Level | $6.44 | $2.61 |
| Resistance Level | $7.29 | $3.50 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 83.62 | 1.29 |
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.